Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 – Pipeline Review, H1 2020

Global Markets Direct’s, ‘Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 (Autotaxin or Extracellular Lysophospholipase D or ENPP2 or EC 3.1.4.39) – Pipeline Review, H1 2020’, provides in depth analysis on Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 (Autotaxin or Extracellular Lysophospholipase D or ENPP2 or EC 3.1.4.39) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 (Autotaxin or Extracellular Lysophospholipase D or ENPP2 or EC 3.1.4.39) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Oncology, Respiratory, Gastrointestinal, Immunology, Central Nervous System, Cardiovascular, Genito Urinary System And Sex Hormones and Musculoskeletal Disorders under development targeting Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 (Autotaxin or Extracellular Lysophospholipase D or ENPP2 or EC 3.1.4.39).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

– The report provides a snapshot of the global therapeutic landscape for Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 (Autotaxin or Extracellular Lysophospholipase D or ENPP2 or EC 3.1.4.39)

– The report reviews Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 (Autotaxin or Extracellular Lysophospholipase D or ENPP2 or EC 3.1.4.39) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved in Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 (Autotaxin or Extracellular Lysophospholipase D or ENPP2 or EC 3.1.4.39) targeted therapeutics and enlists all their major and minor projects

– The report assesses Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 (Autotaxin or Extracellular Lysophospholipase D or ENPP2 or EC 3.1.4.39) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news and deals related to Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 (Autotaxin or Extracellular Lysophospholipase D or ENPP2 or EC 3.1.4.39) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 (Autotaxin or Extracellular Lysophospholipase D or ENPP2 or EC 3.1.4.39)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 (Autotaxin or Extracellular Lysophospholipase D or ENPP2 or EC 3.1.4.39) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Blade Therapeutics Inc

Boehringer Ingelheim International GmbH

Eli Lilly and Co

Fidelta Ltd

Galapagos NV

Galecto Biotech AB

iOnctura SA

LegoChem Biosciences Inc

Ono Pharmaceutical Co Ltd

Ribomic Inc

Sansho Co Ltd

TaiwanJ Pharmaceuticals Co Ltd

X-Rx Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 (Autotaxin or Extracellular Lysophospholipase D or ENPP2 or EC

3.1.4.39) – Overview

Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 (Autotaxin or Extracellular Lysophospholipase D or ENPP2 or EC

3.1.4.39) – Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 (Autotaxin or Extracellular Lysophospholipase D or ENPP2 or EC

3.1.4.39) – Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 (Autotaxin or Extracellular Lysophospholipase D or ENPP2 or EC

3.1.4.39) – Companies Involved in Therapeutics Development

Blade Therapeutics Inc

Boehringer Ingelheim International GmbH

Eli Lilly and Co

Fidelta Ltd

Galapagos NV

Galecto Biotech AB

iOnctura SA

LegoChem Biosciences Inc

Ono Pharmaceutical Co Ltd

Ribomic Inc

Sansho Co Ltd

TaiwanJ Pharmaceuticals Co Ltd

X-Rx Inc

Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 (Autotaxin or Extracellular Lysophospholipase D or ENPP2 or EC

3.1.4.39) – Drug Profiles

2-CCPA – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BBT-877 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BLD-0409 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IOA-289 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ONO-8430506 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PAT-048 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RBM-006 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit ATX and EGFR for Oncology – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit Autotaxin for Central Nervous System and Gastrointestinal Disorders – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit Autotaxin for Oncology – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit Autotaxin for Oncology – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Autotaxin for Idiopathic Pulmonary Fibrosis and Metastatic Lung Cancer – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Autotaxin for Lung Cancer – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Autotaxin for Oncology – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TJC-0265 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TJC-0316 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

X-165 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ziritaxestat – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 (Autotaxin or Extracellular Lysophospholipase D or ENPP2 or EC

3.1.4.39) – Dormant Products

Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 (Autotaxin or Extracellular Lysophospholipase D or ENPP2 or EC

3.1.4.39) – Product Development Milestones

Featured News & Press Releases

Jan 29, 2020: Orphan Drug Designation for GLPG1690 in systemic sclerosis

Dec 05, 2019: Galapagos completes recruitment of NOVESA trial in systemic sclerosis

Sep 29, 2019: Bridge Biotherapeutics presents positive results from phase 1 clinical study of BBT-877 for Idiopathic Pulmonary Fibrosis (IPF) treatments at the ERS International Congress 2019

May 20, 2019: Bridge Biotherapeutics announces data presentation from first-in-human study of BBT-877 for idiopathic pulmonary fibrosis

Jan 24, 2019: X-Rx announces FDA acceptance of IND application for X-165

Jan 16, 2019: Bridge Biotherapeutics announces FDA Orphan Drug Designation for BBT-877 in idiopathic pulmonary fibrosis (IPF)

Jan 07, 2019: Galapagos starts Phase IIa trial of GLPG1690 for systemic sclerosis

Dec 17, 2018: Galapagos reports initiation of ISABELA Phase 3 program with GLPG1690 in patients with Idiopathic Pulmonary Fibrosis (IPF)

Dec 17, 2018: Bridge Biotherapeutics announces FDA clearance of IND for its BBT-877, an autotaxin inhibitor for IPF

Nov 18, 2018: Bridge Biotherapeutics files investigational new drug application for BBT-877, an autotaxin inhibitor for idiopathic pulmonary fibrosis

Aug 22, 2018: Bridge Biotherapeutics presented preclinical study results on BBT-877, an autotaxin inhibitor at the IPF Summit 2018

May 20, 2018: GLPG1690 results in IPF published in The Lancet Respiratory Medicine and presented at ATS

Apr 12, 2018: Galapagos announces ISABELA Phase 3 program in IPF

Aug 09, 2017: GLPG1690 halts disease progression in IPF patients in FLORA Phase 2a trial

Sep 06, 2016: Orphan Drug Designation in European Union for GLPG1690 in idiopathic pulmonary fibrosis

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development by Stage of Development, H1 2020

Number of Products under Development by Therapy Areas, H1 2020

Number of Products under Development by Indications, H1 2020

Number of Products under Development by Companies, H1 2020

Products under Development by Companies, H1 2020

Products under Development by Companies, H1 2020 (Contd..1), H1 2020

Products under Development by Companies, H1 2020 (Contd..2), H1 2020

Number of Products under Investigation by Universities/Institutes, H1 2020

Products under Investigation by Universities/Institutes, H1 2020

Number of Products by Stage and Mechanism of Actions, H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Pipeline by Blade Therapeutics Inc, H1 2020

Pipeline by Boehringer Ingelheim International GmbH, H1 2020

Pipeline by Eli Lilly and Co, H1 2020

Pipeline by Fidelta Ltd, H1 2020

Pipeline by Galapagos NV, H1 2020

Pipeline by Galecto Biotech AB, H1 2020

Pipeline by iOnctura SA, H1 2020

Pipeline by LegoChem Biosciences Inc, H1 2020

Pipeline by Ono Pharmaceutical Co Ltd, H1 2020

Pipeline by Ribomic Inc, H1 2020

Pipeline by Sansho Co Ltd, H1 2020

Pipeline by TaiwanJ Pharmaceuticals Co Ltd, H1 2020

Pipeline by X-Rx Inc, H1 2020

Dormant Projects, H1 2020

List of Figures

List of Figures

Number of Products under Development by Stage of Development, H1 2020

Number of Products under Development by Therapy Areas, H1 2020

Number of Products under Development by Top 10 Indications, H1 2020

Number of Products by Stage and Mechanism of Actions, H1 2020

Number of Products by Routes of Administration, H1 2020

Number of Products by Stage and Routes of Administration, H1 2020

Number of Products by Molecule Types, H1 2020

Number of Products by Stage and Molecule Types, H1 2020

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports